AUA/SUFU/AUGS 绝经泌尿生殖综合征指南
该指南由 AUA/SUFU/AUGS 制定,基于 Minnesota 循证实践中心对 68 篇文献的系统综述及 66 篇非激素干预文献的证据图,围绕绝经泌尿生殖综合征(GSM)的识别、诊断、咨询与治疗给出推荐。诊断基于症状(伴或不伴体征)并排除其他病因;局部低剂量阴道雌激素证据最充分,因证据不足不推荐某种激素疗法优于另一种,强调共享决策。
要点
- GSM 诊断基于症状,伴或不伴体征,需排除其他病因或共病。
- 局部低剂量阴道雌激素证据最充分。
- 证据不足以推荐一种激素疗法优于另一种,不主张阶梯式换药。
核心结论
- GSM 诊断基于症状(伴或不伴体征)并排除其他病因或共病。
- 局部低剂量阴道雌激素证据最充分。
- 证据不足以推荐一种激素疗法优于另一种,指南不主张阶梯式激素换药。
- 治疗应基于共享决策,结合患者目标与偏好及各项干预的疗效与不良事件证据。
研究设计与样本
- 指南由 AUA/SUFU/AUGS 制定,采用循证与共识流程。
- 系统综述基于 Minnesota 循证实践中心受 AHRQ 合同、PCORI 资助的研究。
- 证据实践中心从 68 篇出版物提取并合成疗效和/或危害结局。
- 另在证据图中描述 66 篇评估 46 种非激素干预的出版物。
主要发现
- 存在大量评估激素与非激素治疗管理 GSM 症状的证据。
- 局部低剂量阴道雌激素证据基础最充分。
- 证据不足以推荐一种激素疗法优于另一种。
关键数值与推荐
- GSM 诊断基于症状,伴或不伴相关体征,并排除其他病因或共病。
- 局部低剂量阴道雌激素证据最充分。
- 证据不足以推荐一种激素疗法优于另一种,不主张阶梯式激素换药。
临床怎么用
- 按症状(伴或不伴体征)诊断 GSM 并排除其他病因或共病。
- 治疗选择以共享决策为框架,结合患者目标与偏好。
- 以各项干预的疗效与不良事件证据作为治疗决策指导。
- 不采用不同激素疗法间的阶梯式换药策略。
局限性
- 证据不足以推荐一种激素疗法优于另一种。
- 未就诊断 GSM 所需症状数量或类型达成共识。
- 相关泌尿症状与其他常见泌尿疾病(如膀胱过度活动症)存在重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genitourinary syndrome of menopause (GSM) describes the symptoms and physical changes that result from declining estrogen and androgen concentrations in the genitourinary tract during the menopausal transition. There has not been a consensus reached about the number or type of symptoms needed to diagnose GSM, and the associated urinary symptoms are also linked with other common urologic conditions such as overactive bladder. This guideline provides information to clinicians regarding identification, diagnosis, counseling, and treatment for patients with GSM to optimize symptom control and quality of life while minimizing adverse events. MATERIALS AND METHODS: The systematic review utilized in the creation of this guideline is based on research conducted by the Minnesota Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality and funded by the Patient Centered Outcomes Research Institute. The Evidence-based Practice Center extracted and synthesized effectiveness and/or harms outcomes from 68 publications. An additional 66 publications evaluating 46 non-hormonal interventions, were described in an evidence map. RESULTS: Clinicians diagnose GSM based on symptoms, with or without related physical findings, and after ruling out other etiologies or co-occurring pathologies. There is a large body of evidence examining the use of hormonal and non-hormonal treatment options to manage the symptoms of GSM; however, the local low-dose vaginal estrogen has the most robust evidence base. CONCLUSIONS: The strategies defined in this document were derived from evidence-based and consensus-based processes. Given that there is insufficient information to recommend one hormonal therapy over another, this guideline is not meant to support a stepwise progression through different hormonal approaches. The clinician should make treatment decisions in the context of shared decision-making considering patient goals and preferences, using the evidence of efficacy and adverse events of each possible intervention as a guide.
引用
- Kaufman MR, Ackerman AL, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025. PMID: 40298120. doi:10.1097/JU.0000000000004589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。